생물제제 임상시험 수탁기관 시장 : 업계 동향과 세계 예측 - 생물제제 유형별, 사업 규모별, 치료 영역별, 지역별

Biologics Contract Research Organization Market: Industry Trends and Global Forecasts - Distribution by Type of Biologic, Scale of Operation, Therapeutic Area, and Geography

US $ 4,799 ￦ 6,650,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,699,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,688,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,943,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

생물제제 임상시험 수탁기관 시장 : 개요

세계의 생물제제 임상시험 수탁기관 시장 규모는 올해 215억 달러에 달했습니다. 이 시장은 예측 기간 중 13%의 유리한 CAGR로 성장할 것으로 예측됩니다.

시장 세분화에서는 시장 규모와 기회 분석을 다음과 같은 매개 변수로 구분합니다.

생물제제 유형

• 백신
• 세포치료
• 유전자 치료
• 항체
• 재조합 단백질/펩티드
• 기타

사업 규모

• 임상사업
• 전임상 사업

치료 영역

• 암 영역
• 심혈관 질환
• 염증성 질환
• 신경질환
• 기타

지역

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 북아프리카
• 기타 지역

생물제제 의약품 개발 수탁기관 시장 : 성장과 동향

생물제제는 제약 산업에서 가장 빠르게 성장하는 분야 중 하나입니다. 이는 효과적이고 개별화된 약리학적 개입의 필요성으로 인해 이 분야의 기술 혁신이 빠르게 진행되고 있기 때문입니다. 그러나 생물제제의 개발과 임상시험은 매우 복잡하고 비용이 많이 드는 과정으로, 전문 지식과 첨단 바이오프로세스 기술이 요구됩니다. 그 결과, 많은 생물제제 기업이 신약개발 및 임상연구 업무의 아웃소싱을 선택하고 있습니다.

현재 바이오의약품 기업은 개발 프로세스를 외부 서비스 프로바이더에 위탁하고, 자신들은 의약품 연구개발을 책임지는 비즈니스 모델을 채택하고 있습니다. 이러한 외부 연구 서비스 프로바이더는 다양한 생물제제 개발 위탁기관(CRO)으로서, 일반적으로 개발 기업이 담당하는 한 가지 이상의 책임을 맡고 있습니다. 이러한 책임의 예로는 프로토콜 설계, 임상시험의 선택 또는 모니터링, 보고서 평가, 미국 FDA에 제출할 서류 작성 등이 있습니다. 바이오의약품 CRO가 제공하는 주요 이점으로는 시간 효율성, 비용 효율성, 기술 혁신의 열쇠, 품질 혁신 등이 있습니다. 그 결과, 생물제제 개발 업무 위탁기관 시장은 생물제제 스폰서 증가하는 연구개발 수요를 충족시키기 위해 점차 확대될 것으로 예측됩니다.

생물제제 개발 위탁기관 시장 : 주요 인사이트

이 보고서에서는 생물제제 개발 업무 위탁 시장의 현황을 조사하고, 잠재적인 성장 기회를 파악했습니다. 주요 조사 결과는 다음과 같습니다.

• 현재 160개 기업이 다양한 유형의 생물제제 관련 개발 업무 위탁 서비스 및 임상시험 지원을 제공하는 데 필요한 역량을 보유하고 있다고 주장하고 있습니다.
• 전체의 약 50%가 임상 서비스만을 제공하고 있으며, 그 중 12%의 CRO가 생물제제 임상연구와 관련된 모든 서비스를 제공합니다.
• 현재 시장 상황은 파편화되어 있으며, 전임상 및 임상 연구를 지원하는 광범위한 포트폴리오를 보유한 기존 기업과 전문 서비스 프로바이더가 혼재되어 있습니다.
• 대형 제약사들은 현재 사내 연구개발 업무의 45% 가량을 CRO에 위탁하고 있는 것으로 추정됩니다.
• 개발업무 수탁기업의 3분의 2 이상이 북미와 유럽에 기반을 두고 있으며, 대부분 중소기업입니다.
• 경쟁 우위를 확보하기 위해 각 사들은 기존 역량을 적극적으로 확장하고 서비스를 더욱 강화하는 한편, 진화하는 업계 벤치마킹에 대응하고 있습니다.

• 현재 8,000개 이상의 제품 후보물질이 생물제제 개발 기업에서 평가/개발 중으로, 생물제제 개발 업무 위탁 시장에 기회를 제공합니다.
• 이 분야에 대한 이해관계자들의 관심이 높아짐에 따라 최근 제휴 활동이 증가하고 있으며, 2016년 이후 업계 진출기업은 스폰서 및/또는 다른 CRO와 여러 계약을 체결하고 있습니다.
• CRO의 약 20%가 임상 및 전임상 규모의 생물제제 연구 서비스를 제공합니다.
• 원스톱 쇼핑에 대한 수요가 증가함에 따라 업계 이해관계자들은 주로 M&A 및 내부 확장을 통해 생물제제 연구와 관련된 역량을 적극적으로 통합하고 있습니다.

• 이 시장은 향후 10년간 CAGR -13% 성장할 것으로 예상되며, 치료영역별, 사업 규모별, 생물제제 유형별, 최종사용자별, 지역별 기회가 고르게 분포되어 있을 것으로 예측됩니다.

생물제제 임상시험 수탁기관 시장의 참여 기업 예

• Biocon
• Covance
• ICON
• Medpace
• Pharmaron
• PPD
• PRA Health Sciences
• Syneos Health
• Vimta Labs
• WuXi AppTec

목차

제1장 서문

제2장 개요

제3장 서론

제3장 서론

• 챕터 개요
• 생물제제의 개요
• 의약품 조사 수탁 기관(CRO)의 개요
• CRO의 진화
• CRO의 분류
• CRO가 제공하는 서비스
• CRO에 대한 업무 아웃소싱의 이점
• CRO에 대한 업무 아웃소싱에 수반하는 리스크

제4장 아웃소싱 가이드

• 챕터 개요
• 생물제제 조사의 아웃소싱
• 아웃소싱의 모델
• 적절한 아웃소싱 모델의 선택
• CRO 파트너의 선택
• 의약품 개발 프로세스에서 CRO의 역할
• 결론

제5장 시장 구도

• 챕터 개요
• 생물제제 CRO : 시장 구도
• 전임상 생물제제 CRO
• 임상 생물제제 CRO

제6장 기업 개요

• 챕터 개요
• Biocon
• Covance
• ICON
• Medpace
• Pharmaron
• PPD
• PRA Health Sciences
• Syneos Health
• Vimta Labs
• WuXi AppTec

제7장 벤치마크 분석

• 챕터 개요
• 조사 방법
• 벤치마크 분석 : 피어 그룹

제8장 파트너십과 협업

• 챕터 개요
• 파트너십 모델
• 생물제제 CRO : 최근 파트너십과 협업

제9장 합병과 인수

제10장 매력과 경쟁력 매트릭스

제11장 시장 예측

• 챕터 개요
• 예측 조사 방법과 주요 전제조건
• 세계의 생물제제 CRO 시장
• 북미의 생물제제 CRO 시장
• 유럽의 생물제제 CRO 서비스 시장
• 아시아태평양의 생물제제 CRO 서비스 시장
• 라틴아메리카의 생물제제 CRO 서비스 시장
• 라틴아메리카의 생물제제 CRO 서비스 시장

제12장 SWOT 분석

제13장 결론

제14장 조사 기록

제15장 부록 I : 표형식 데이터

제16장 부록 II : 기업 및 조직 리스트

KSA

영문 목차

영문목차

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: OVERVIEW

As per Roots Analysis, the global biologics contract research organization market valued at USD 21.5 billion in the current year is anticipated to grow at a lucrative CAGR of 13% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biologic

• Vaccines
• Cell Therapy
• Gene Therapy
• Antibodies
• Recombinant Proteins / Peptides
• Others

Scale of Operation

• Clinical Operations
• Preclinical Operations

Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Inflammatory Disorders
• Neurological Disorders
• Other Therapeutic Areas

Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa
• Rest of the World

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: GROWTH AND TRENDS

Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can

be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized pharmacological interventions. However, the development and clinical testing of biologics is a highly complex and costly process that demands specialized expertise and advanced bioprocessing technologies. As a result, many biopharmaceutical companies are choosing to outsource their drug discovery and clinical research operations.

Currently, biopharmaceutical companies are embracing a business model, wherein the development processes are outsourced to external service providers, whereas the company itself is responsible for the R&D of drugs. These external research service providers are various biopharma contract research organizations (CRO) that take on one or more responsibilities typically held by a developer. Examples of such responsibilities include protocol design, selection or monitoring of investigations, evaluation of reports, and preparation of documentation for submission to the US FDA. Key advantages offered by biopharma CRO include time efficiency, cost effectiveness, key to innovation, and quality innovation. Consequently, the biologics contract research organization market is anticipated to expand gradually to fulfil the growing R&D demands of biopharmaceutical sponsors.

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: KEY INSIGHTS

The report delves into the current state of the biologics contract research organization market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, 160 players claim to have the necessary capabilities to offer contract research services and clinical trial support for different types of biopharmaceutical products.
• About 50% of all the players offer only clinical services; of these, 12% CROs provide all the services associated with clinical research of biologics.
• The current market landscape is fragmented, featuring a mix of well-established players and specialty service providers, having extensive portfolios to support preclinical and clinical research.
• It is estimated that big pharma players presently outsource close to 45% of their internal R&D operations to CROs.
• More than two-thirds of the contract research service providers are based in North America and Europe; most of these players are small and mid-sized companies.
• In order to gain a competitive edge, companies are actively expanding their existing capabilities in order to further augment their respective offerings and also comply with evolving industry benchmarks.

• Over 8,000 product candidates are currently being evaluated / under development biologic drug developers, presenting opportunities in the biologics contract research organization market.
• The growing interest of stakeholders in this field is also reflected in the increase in partnership activity in the recent past; since 2016, industry players have signed multiple deals with sponsor and / or other CROs.
• Close to 20% of the CROs provide research services for biologics at the clinical and preclinical scales.
• With the rising demand for one-stop shops, industry stakeholders are actively consolidating their capabilities related to biopharmaceutical research, mostly through mergers and acquisitions, and internal expansions.

• The market is expected to grow at a CAGR of ~13% in the coming decade; the opportunity is likely to be well distributed across therapeutic areas, scales of operation, types of biologics, end users and geographical regions.

Example Players in the Biologics Contract Research Organization Market

• Biocon
• Covance
• ICON
• Medpace
• Pharmaron
• PPD
• PRA Health Sciences
• Syneos Health
• Vimta Labs
• WuXi AppTec

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global biologics contract research organization market, focusing on key market segments, including [A] type of biologic, [B] scale of operation, [C] therapeutic area and [D] geography.
• Market Landscape: A comprehensive evaluation of the biopharmaceutical services market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] types of biologics manufactured, [E] scale of operation and [F] types of services offered (including clinical services and preclinical services).
• Company Profiles: In-depth profiles of CROs engaged in offering biopharmaceutical related services, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio and [D] recent developments and an informed future outlook.
• Benchmarking Analysis: A comprehensive benchmark analysis of players engaged in biologics contract research organization market based on the [A] capabilities of companies with a peer groups with an aim to gain a competitive edge.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the biologics contract research organization market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] most active players (in terms of number of partnerships signed), [D] scale of operation and [E] geography.
• Mergers and Acquisitions: An in-depth analysis of the mergers and acquisitions undertaken in this domain, based on relevant parameters, such as [A] year of acquisition, [B] type of collaboration, [C] geography, [D] most active acquirers, [E] ownership change matrix, [F] key value drivers and [G] acquisition deal multiples.
• Attractiveness Competitiveness Matrix: A comprehensive acquisition target analysis, considering the historical trend of the activity of companies that have acquired other firms since 2016, and providing a means for other industry players to identify potential acquisition targets.
• SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of biologics contract research organization market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3 Introduction

• 3.1. Chapter Overview
• 3.2. Overview of Biologics
  • 3.2.1. Types of Biologics
• 3.3. Overview of Contract Research Organizations (CROs)
• 3.4. Evolution of CROs
• 3.5. Classification of CROs
• 3.6. Services Offered by CROs
• 3.7. Advantages of Outsourcing Operations to CROs
• 3.8. Risks Associated with Outsourcing Operations to CROs

4. GUIDE TO OUTSOURCING

• 4.1. Chapter Overview
• 4.2. Outsourcing Biologics Research
• 4.3. Models of Outsourcing
  • 4.3.1. Transactional Outsourcing Model
  • 4.3.2. Performance / Outcome-based Business Model
  • 4.3.3. Staff Augmentation Model
  • 4.3.4. Phase-Dependent Outsourcing Model
• 4.4. Selecting an Appropriate Outsourcing Model
  • 4.4.1. Hybrid Approach
• 4.5. Selecting a CRO Partner
  • 4.5.1. Key Considerations for Outsourcing Biologics-related Operations
• 4.6. Role of CROs in the Drug Development Process
  • 4.6.1. Discovery and Preclinical Research
  • 4.6.2. Early Clinical Research
  • 4.6.3. Clinical Research and Laboratory Services
• 4.7. Conclusion

5. MARKET LANDSCAPE

• 5.1. Chapter Overview
• 5.2. Biopharmaceutical CROs: Overall Market Landscape
  • 5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
  • 5.2.2. Analysis by Scale of Operation
• 5.3. Preclinical Biopharmaceutical CROs
  • 5.3.1. Analysis by Year of Establishment
  • 5.3.2. Analysis by Company Size
  • 5.3.3. Analysis by Location of Headquarters
  • 5.3.4. Analysis by Type of Biologic
  • 5.3.5. Analysis by Type of Services Offered
• 5.4. Clinical Biopharmaceutical CROs
  • 5.4.1. Analysis by Year of Establishment
  • 5.4.2. Analysis by Company Size
  • 5.4.3. Analysis by Location of Headquarters
  • 5.4.4. Analysis by Type of Biologics
  • 5.4.5. Analysis by Type of Services Offered

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. Biocon
  • 6.2.1. Company Overview
  • 6.2.2. Financial Information
  • 6.2.3. Services Portfolio
  • 6.2.4. Future Outlook
• 6.3. Covance
  • 6.3.1. Company Overview
  • 6.3.2. Service Portfolio
  • 6.3.3. Financial Information
  • 6.3.4. Future Outlook
• 6.4. ICON
  • 6.4.1. Company Overview
  • 6.4.2. Financial Information
  • 6.4.3. Service Portfolio
  • 6.4.4. Future Outlook
• 6.5. Medpace
  • 6.5.1. Company Overview
  • 6.5.2. Financial Information
  • 6.5.3. Service Portfolio
  • 6.5.4. Future Outlook
• 6.6. Pharmaron
  • 6.6.1. Company Overview
  • 6.6.2. Services Portfolio
  • 6.6.3. Future Outlook
• 6.7. PPD
  • 6.7.1. Company Overview
  • 6.7.2. Service Portfolio
  • 6.7.3. Financial Information
  • 6.7.4. Future Outlook
• 6.8. PRA Health Sciences
  • 6.8.1. Company Overview
  • 6.8.2. Financial Information
  • 6.8.3. Service Portfolio
  • 6.8.4. Future Outlook
• 6.9. Syneos Health
  • 6.9.1. Company Overview
  • 6.9.2. Financial Information
  • 6.9.3. Services Portfolio
  • 6.9.4. Future Outlook
• 6.10. Vimta Labs
  • 6.10.1. Company Overview
  • 6.10.2. Services Portfolio
  • 6.10.3. Financial Information
  • 6.10.4. Future Outlook
• 6.11. WuXi AppTec
  • 6.11.1. Company Overview
  • 6.11.2. Financial Information
  • 6.11.3. Service Portfolio
  • 6.11.4. Future Outlook

7. BENCHMARK ANALYSIS

• 7.1. Chapter Overview
• 7.2. Methodology
• 7.3. Benchmark Analysis: Peer Groups
  • 7.3.1. Peer Group I
  • 7.3.2. Peer Group II
  • 7.3.3. Peer Group III
  • 7.3.4. Peer Group IV
  • 7.3.5. Peer Group V
  • 7.3.6. Peer Group VI
  • 7.3.7. Peer Group VII
  • 7.3.8. Peer Group VIII

8. PARTNERSHIPS AND COLLABORATIONS

• 8.1. Chapter Overview
• 8.2. Partnership Models
• 8.3. Biopharmaceutical CROs: Recent Partnerships and Collaborations
  • 8.3.1. Analysis by Year of Partnership
  • 8.3.2. Analysis by Type of Partnership Model
    • 8.3.2.1. Analysis by Year of Partnership and Type of Partnership Model
  • 8.3.3. Most Active Players: Analysis by Number of Partnerships
  • 8.3.4. Analysis by Scale of Operation
  • 8.3.5. Analysis by Geography
    • 8.3.5.1. Country-wise Analysis
    • 8.3.5.2. Intercontinental and Intracontinental Agreements

9. MERGERS AND ACQUISITIONS

• 9.1. Chapter Overview
• 9.2. Merger and Acquisition Models
• 9.3. Biopharmaceutical CROs: Mergers and Acquisitions
  • 9.3.1. Analysis by Year of Acquisition
  • 9.3.2. Analysis by Type of Collaboration
  • 9.3.3. Analysis by Geography
    • 9.3.3.1. Continent-wise Distribution
    • 9.3.3.2. Country-wise Distribution
  • 9.3.4. Ownership Change Matrix
  • 9.3.5. Most Active Acquirers: Analysis by Number of Acquisitions
• 9.4. Distribution by Key Value Drivers
  • 9.4.1. Analysis by Key Value Drivers
  • 9.4.2. Analysis by Key Value Drivers and Year of Acquisitions
• 9.5. Valuation Analysis: Acquisition Deal Multiples

10. ATTRACTIVENESS COMPETATIVENESS MATRIX

• 10.1. Chapter Overview
• 10.2. AC Matrix: Overview
  • 10.2.1. Strong Business Segment
  • 10.2.2. Average Business Segment
  • 10.2.3. Weak Business Segment
• 10.3. Analytical Methodology
• 10.4. AC Matrix: Contract Manufacturing Scenario in North America
• 10.5. AC Matrix: Contract Manufacturing Scenario in Europe
• 10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East

11. MARKET FORECAST

• 11.1. Chapter Overview
• 11.2. Forecast Methodology and Key Assumptions
• 11.3. Global Biopharmaceutical CROs Market
  • 11.3.1. Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
  • 11.3.2. Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
  • 11.3.3. Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
  • 11.3.4. Global Biopharmaceutical CROs Market: Distribution by Geography
• 11.4. Biopharmaceutical CROs Market in North America
  • 11.4.1. Biopharmaceutical CROs Market in North America: Distribution by Therapeutic Area
    • 11.4.1.1. Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035
    • 11.4.1.2. Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035
    • 11.4.1.3. Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035
    • 11.4.1.4. Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035
    • 11.4.1.5. Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035
  • 11.4.2. Biopharmaceutical CROs Market in North America: Distribution by Scale of Operation
    • 11.4.2.1. Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035
    • 11.4.2.2. Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035
• 11.5. Biopharmaceutical CRO Services Market in Europe
  • 11.5.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Europe
    • 11.5.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Europe, Till 2035
    • 11.5.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Europe, Till 2035
    • 11.5.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Europe, Till 2035
    • 11.5.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Europe, Till 2035
    • 11.5.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Europe, Till 2035
  • 11.5.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Europe
    • 11.5.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Europe, Till 2035
    • 11.5.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Europe, Till 2035
• 11.6. Biopharmaceutical CRO Services Market in Asia-Pacific
  • 11.6.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Asia-Pacific
    • 11.6.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Asia-Pacific, Till 2035
    • 11.6.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Asia-Pacific, Till 2035
    • 11.6.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Asia-Pacific, Till 2035
    • 11.6.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Asia-Pacific, Till 2035
    • 11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Asia-Pacific, Till 2035
  • 11.6.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Asia-Pacific
    • 11.6.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Asia-Pacific, Till 2035
    • 11.6.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Asia-Pacific, Till 2035
• 11.7. Biopharmaceutical CRO Services Market in Latin America
• 11.8. Biopharmaceutical CRO Services Market in Middle East North America

12. SWOT ANALYSIS

• 12.1. Chapter Overview
• 12.2. Strengths
• 12.3. Weaknesses
• 12.4. Opportunities
• 12.5. Threats
• 12.6. Comparison of SWOT Factors

13. CONCLUDING REMARKS

• 13.1. Chapter Overview

14. SURVEY TRANSCRIPTS

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

관련자료